These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21353142)

  • 1. The real mechanism of VPA-induced hyperammonemia remains unknown.
    Hung CC; Li TM; Wei IH; Huang CC
    Gen Hosp Psychiatry; 2011; 33(1):84.e3-4. PubMed ID: 21353142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
    Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproate-associated hyperammonemic encephalopathy.
    Wadzinski J; Franks R; Roane D; Bayard M
    J Am Board Fam Med; 2007; 20(5):499-502. PubMed ID: 17823470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for hyperammonemia in pediatric patients with epilepsy.
    Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
    Larsen EP; Ostergaard JR
    Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management.
    Chopra A; Kolla BP; Mansukhani MP; Netzel P; Frye MA
    Gen Hosp Psychiatry; 2012; 34(3):290-8. PubMed ID: 22305367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
    Cheng M; Tang X; Wen S; Yue J; Wang H
    Compr Psychiatry; 2013 Jul; 54(5):562-7. PubMed ID: 23246073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
    Yagi M; Nakamura T; Okizuka Y; Oyazato Y; Kawasaki Y; Tsuneishi S; Sakaeda T; Matsuo M; Okumura K; Okamura N
    Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
    Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
    Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe acute hyperammonemia after brief exposure to valproate.
    Eubanks AL; Aguirre B; Bourgeois JA
    Psychosomatics; 2008; 49(1):82-3. PubMed ID: 18212182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of hyperammonaemic encephalopathy due to valproic acid.
    Prins MC; van Meijel JJ
    Neth J Med; 2011 Sep; 69(9):389-91. PubMed ID: 21978982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperammonaemic encephalopathy due to valproic acid].
    Durán-Ferreras E; Jiménez-Vilches PL; Galá-Barranco JM; Fernández-Bolaños Porras R
    Rev Neurol; 2008 May 1-15; 46(9):537-9. PubMed ID: 18446695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lacosamide-induced valproic acid toxicity.
    Jones GL; Popli GS; Silvia MT
    Pediatr Neurol; 2013 Apr; 48(4):308-10. PubMed ID: 23498565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
    Mojumder DK; De Oleo RR
    Indian J Pharmacol; 2014; 46(3):345-7. PubMed ID: 24987188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Valproate-induced hyperammonemic encephalopathy in a patient with Sjögren's syndrome].
    Nakazato Y; Ando S; Yamamoto T; Tamura N; Shimazu K
    Rinsho Shinkeigaku; 2004 Oct; 44(10):682-5. PubMed ID: 15568484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS.
    Garcia M; Huppertz HJ; Ziyeh S; Buechert M; Schumacher M; Mader I
    Epilepsia; 2009 Mar; 50(3):486-92. PubMed ID: 19183221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
    Gerstner T; Buesing D; Longin E; Bendl C; Wenzel D; Scheid B; Goetze G; Macke A; Lippert G; Klostermann W; Mayer G; Augspach-Hofmann R; Fitzek S; Haensch CA; Reuland M; Koenig SA
    Seizure; 2006 Sep; 15(6):443-8. PubMed ID: 16787750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.